How does genomic tumour profiling work?

A specialist usually starts with tissue already collected during a biopsy or surgery. The laboratory extracts tumour DNA, and sometimes RNA, then reads selected genes or a broader set of genes using sequencing technology. The report describes changes found in the sample and may group them by whether they could influence treatment, explain tumour behaviour, or qualify for further discussion.

The result is not a diagnosis by itself. It is interpreted alongside the tumour location, stage, previous pathology, general health, and treatments already given. A finding may point toward a targeted therapy, an immunotherapy discussion, or a clinical trial, while some findings have no useful treatment match. A sample can also be insufficient or contain too little tumour material, so a repeat sample may be discussed.

Ask which sample will be tested, what the test is designed to find, and when the report is expected. Take the report to the oncology appointment and ask which findings are actionable for your cancer today. If a targeted option is suggested, ask how it would be given, what monitoring it needs, and how it fits with other choices. Profiling can be relevant in cancers such as bowel, lung, ovarian, or cancer of unknown primary, but its value depends on the individual case.

Contact your oncology team if you are unsure whether a reported finding changes your current treatment or if a result is difficult to understand. Seek urgent medical advice for new severe symptoms, such as trouble breathing, confusion, heavy bleeding, or rapidly worsening pain; these need assessment regardless of the profiling result.

What exactly was tested, and was the sample adequate? Which finding matters most for my treatment plan? Does the result support targeted therapy, and what are the alternatives? Could the result affect relatives, or is it limited to the tumour?